S. Faucette

发表

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

Geraldine A Hamilton, Hongbing Wang, E. Lecluyse, 2004, Drug metabolism and disposition: the biological fate of chemicals.

The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.

Hongbing Wang, G. Hamilton, C. Lindley, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development

K. Venkatakrishnan, S. Faucette, A. Trivedi, 2017, Clinical and translational science.

Modulation of UDP‐glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers

C. Smith, Hongbing Wang, S. Faucette, 2005, Journal of biochemical and molecular toxicology.

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

F. Bosch, L. Gordon, J. Radford, 2016 .

Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing

M. Socinski, C. Lindley, J. McCune, 2001, Cancer Chemotherapy and Pharmacology.

Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.

C. Lindley, S. Faucette, S. Shord, 2001, Drug metabolism and disposition: the biological fate of chemicals.

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

J. Sosman, A. Ribas, P. LoRusso, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

C. Lindley, B. Yan, S. Faucette, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers

Hongbing Wang, T. Sueyoshi, M. Negishi, 2007, Journal of Pharmacology and Experimental Therapeutics.

Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin*

Hongbing Wang, T. Sueyoshi, M. Negishi, 2004, Journal of Biological Chemistry.

A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression*

Hongbing Wang, T. Sueyoshi, M. Negishi, 2003, The Journal of Biological Chemistry.

Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor

C. Smith, Hongbing Wang, T. Sueyoshi, 2006, Journal of Pharmacology and Experimental Therapeutics.

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

R. Neuwirth, J. Sosman, A. Ribas, 2016, Investigational New Drugs.

Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes.

Hongbing Wang, T. Sueyoshi, M. Negishi, 2003, Drug metabolism and disposition: the biological fate of chemicals.

A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer

M. Socinski, M. Kirstein, C. Stewart, 2005, Cancer investigation.

Phase I trial of topotecan (T) carboplatin (C) and etoposide (E) for extensive stage small cell lung cancer (ES-SCLC)

M. Socinski, S. Shifflett, C. Lindley, 2000 .

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer

M. Socinski, C. Lindley, S. Faucette, 2003, Cancer Chemotherapy and Pharmacology.

a Phase 1b/2 Study of TAK-659, an Investigational Dual SYK and FLT-3 Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

O. Frankfurt, K. Kannan, Benjamin H. Lee, 2016 .

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.

R. Neuwirth, J. Sosman, A. Ribas, 2013 .

MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.

R. Neuwirth, M. Kneissl, D. Rasco, 2013 .